Clin2
NCT03764098Possibly a fitRecruiting

Guanfacine to reduce heavy drinking in adults with alcohol use disorder

Alcohol Use

Part of Mental health clinical trials.

This Phase 2 study tests whether guanfacine can reduce drinking in women and men who drink heavily and meet criteria for alcohol use disorder. It also looks at how the medicine affects drinking patterns in a controlled setting.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
160 people
Ages
21 years to 70 years
Study type
Interventional

Who can take part

  • You’re between 21 and 70 years old.
  • You can read and write English.
  • You meet criteria for alcohol use disorder based on your drinking over the last 6 months, including heavy daily drinking patterns for at least 30 days before the study.
  • You can take pills by mouth, can follow the medication schedule, and are willing to cut down on drinking during treatment.
  • You agree not to use certain drugs right before starting (including some anxiety and antidepressant medicines in the last 30 days and any illegal drugs).
  • You must not be pregnant or nursing, and must use birth control (if applicable). Only one person per household can join.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT04084860Recruiting· Phase 2
Brief medicine trial to help reduce heavy alcohol drinking

This Phase 2 study tests a brief medication approach meant to reduce “problem drinking.” It may help people cut back or stop alcohol use by adjusting brain signaling related to drinking cravings and urges.

New York, New York
NCT04135846Recruiting· Phase 2
Alpha-blocker medicine to help reduce alcohol drinking

This Phase 2 trial tests whether blocking certain body signals (alpha receptors) with a study medicine can help people with alcohol use disorder cut down or stop drinking. You may be able to join if you meet alcohol-use criteria and can safely take the study drug.

Providence, Rhode Island
NCT07520292Recruiting· Phase 1
Testing NTX-2001 to reduce drinking in alcohol use disorder

This study tests whether a new medication called NTX-2001 can help people with alcohol use disorder drink less. Researchers will measure how the drug affects alcohol consumption and safety in adults aged 21–60.

New Haven, Connecticut
NCT06900998Not yet recruiting· Phase 2
Nimodipine study for heavy drinkers

This trial tests if a blood pressure medication called nimodipine can help reduce alcohol drinking in people with moderate to severe alcohol use disorder. You'll take the medication or a placebo and participate in drinking sessions to see how it affects your alcohol intake.

New Haven, Connecticut
NCT06642181Recruiting· Phase 1
Guanfacine and meditation with buprenorphine for opioid use disorder

This study tests if adding a medication called guanfacine and mindfulness meditation to standard buprenorphine treatment helps people with opioid use disorder. It looks at whether this combination can improve treatment outcomes and reduce opioid use.

Newark, New Jersey
NCT07681869Not yet recruiting· Phase 2
Can nimodipine help reduce drinking?

This study tests whether a blood pressure medication called nimodipine can help reduce drinking in people with alcohol use disorder. If you are a heavy drinker and not seeking treatment right now, you may be able to join.

New Haven, Connecticut

Hear when a new Alcohol Use trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.